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mespite the demonstrated value of heart failure (HF) disease
anagement, many questions remain. Which program ele-
ents contribute most toward the observed benefits? What
atient characteristics predict benefit? Importantly, do ben-
fits persist beyond the intervention period? In this issue of
he Journal, Ferrante et al. (1) bring us closer to answers,
eporting clinical outcomes over 3 years after completion of
randomized, controlled disease management intervention
n an Argentine population with stable HF. The observed
ersistent reduction of death or HF hospitalization helps us
oward understanding the mechanism of benefit of disease
anagement, developing an approach toward its cost-
ffective deployment, and establishing policy related to this
rowing and costly health care problem.
See page 372
A meta-analysis of remote telemonitoring (2) demon-
trated reduced rates of HF hospitalization and mortality.
hree of 6 trials showed improved health-related quality of
ife, and 3 of 4 demonstrated health care cost reduction. But
number of recent trials have failed to demonstrate benefit,
nd analyses have failed to provide adequate description of
opulations and interventions (3,4). Although findings have
ot been uniform, if the key elements can be identified and
pplied to appropriate populations, there is significant
otential for improving health care outcomes and cost of
are.
Applying and simplifying a proposed disease manage-
ent taxonomy (5), elements of HF programs might be
rouped into 3 categories: 1) monitoring and fluid manage-
ent; 2) sustained therapeutic modifications; and 3) patient
ducation. Monitoring, which may be telephone based or
ay incorporate telemonitoring technology, is designed to
etect changes in fluid and/or hemodynamic status and
vidence of disease activity and implement short-term
nterventions to restore stability and prevent hospitalization.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Cardiovascular Center and the Division of Cardiology, Department of
edicine, Tufts Medical Center and Tufts University School of Medicine, Boston,t
assachusetts; and the ‡Department of Counseling and School Psychology, Univer-
ity of Massachusetts, Boston, Massachusetts.ustained therapeutic modifications may include optimizing
rescription and dosing of drugs with known benefits on
isease progression. Education is directed toward improving
atient adherence to medication and dietary prescriptions
nd toward self-monitoring and response to changes in
linical status.
The analysis performed by Ferrante et al. (1) provides
ew insights into the value of different program components
or achieving sustained clinical benefit, placing emphasis on
atient adherence. Patients who showed the greatest im-
rovement in adherence also showed the greatest reduction
n rates of the primary outcome end point, principally by a
eduction in HF hospitalizations. Patients randomly as-
igned to the active intervention also had higher achieved
sage rates for beta-blockers and spironolactone, with a
avorable trend for angiotensin-converting enzyme inhibi-
ors. Therefore, it seems likely that 2 of these 3 categories of
F program elements—sustained therapeutic modifications
nd education—contributed to the sustained benefit. Tele-
hone monitoring may have contributed to the benefits
uring the initial year of intervention, but seems unlikely to
ave contributed to the sustained benefits.
Few analyses have focused on the sustainability of benefit
fter discontinuation of the intervention. Estimating sus-
ainability and understanding the factors that might gener-
te sustained benefit are critical in projecting a program’s
ost effectiveness. A program’s value would be substantially
agnified with the knowledge that the outcome benefits
ould be sustained after selectively discontinuing the active
ntervention at a specific time point or under specific clinical
ircumstances.
Rich et al. (6) demonstrated improved medication adher-
nce and reduced rehospitalization rate (7) during a 90-day
ultidisciplinary intervention for a population of predom-
nantly elderly, African-American women with a high rate
f systolic hypertension and a relatively low baseline usage of
ngiotensin-converting enzyme inhibitors and beta-
lockers. The authors noted a persistent reduction in the
eadmission rate during the 9 months after discontinuation
f the intervention. It is likely that all 3 categories of
anagement elements—monitoring, sustained therapeutic
odification, and education—contributed to the overallreatment benefit. In particular, more effective antihyper-
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istory of the underlying disease.
In contrast, we designed a trial to assess the sustainability
f benefit of a 3-month telemonitoring intervention and
ound regression of the reduced HF hospitalization rate
bserved during the active intervention, after selective with-
rawal to a more passive phase (8). Our population had
igher baseline angiotensin-converting enzyme inhibitor
nd beta-blocker use than that of Rich et al. (6), with little
ongitudinal change in utilization or dosing. Although our
rogram included education regarding adherence and self-
onitoring, it is likely that effective educational efforts also
ook place within the control population. Although the
ntervention was cost effective at reducing 90-day HF-
elated events, we did not demonstrate a net cost savings (9).
n a more recent trial, we showed incremental impact of
ctive electronic telemonitoring, compared with telephone-
ased monitoring, on HF rehospitalization, although not of
ll-cause hospitalization (10). Our findings indicate that in
n otherwise well-managed population, telemonitoring-
ased reduction in HF hospitalization rates are maintained
nly as long as the intervention is applied.
Deploying an intervention emphasizing patient educa-
ion, but also including home telemonitoring, Krumholz et
l. (11) showed reduced rate of death or readmission, with
net cost savings of $6,985 per patient. The work by
errante et al. (1) suggests that even more cost-effective
trategies can be constructed by intensively focusing on
ppropriate prescription and patient adherence during tar-
eted time frames, while selectively engaging in telemoni-
oring for a limited period. Further work is needed to
etermine the incremental value of continued monitoring of
table patients, and whether it justifies the ongoing cost.
Unlike most such trials, Ferrante et al. (1) enrolled a
road ambulatory population, without a requirement for
ecent hospitalization. However, cost effectiveness should
ncrease by targeting patients with the highest likelihood of
dverse events and the greatest opportunity for improve-
ent in adherence and/or drug prescription. Applicability
o other populations depends on replicating improvement in
dherence to a degree similar to that observed by these
uthors. Although much of the population variability in
dherence remains unexplained, Wu et al. (12) found that
edication adherence was the major factor linking ethnicity
o clinical outcomes. Other factors linked to adherence
nclude income, rates of depression, availability of social
upport, and out-of-pocket prescription costs (6,13–15). As
ncouraging as are the findings of Ferrante et al. (1), caution
s needed in considering their generalizability to other
atient groups with differing disease, treatment, socioeco-
omic, and cultural characteristics.
The newly observed long-term benefits speak to the need
or our health care reimbursement model to transition to
ne that gives incentive to providers to implement appro-
riately targeted disease management programs. Although
isease management trials have not uniformly demonstratedost saving, they have generally achieved a cost-effective
eduction in the rates of major HF events. The primary end
oint benefits observed by Ferrante et al. (1) were driven
xclusively by reduced rates of rehospitalization, although
unctional class was also improved. Others studies have
uggested reduced mortality (16,17). The marginal costs
ssociated with these benefits are likely to fall well within
he cost-effective range.
The prevalent U.S. model of reimbursing episodes of care
ails to facilitate disease management. The current focus on
educing 30-day rehospitalization rates may have unin-
ended consequences, such as focusing programs exclusively
n the first 30 days after discharge—a far cry from the
-year intervention offered by Ferrante et al. (1)—and
elaying a needed rehospitalization until after the 30-day
indow. We need a shift from payment for episodes of care
o reimbursing continuity of care for a given population
18). The medical home concept provides for sustained,
rganized, interdisciplinary management of complex condi-
ions such as HF. A key to its success is financial alignment,
undling payments for patient populations to groups of
roviders, as through the accountable care organization.
lthough there are several challenges to implementing such
n approach (18), particularly managing the actuarial risk
ithin HF populations, it is the model that will give the
ost incentive to providers to design and implement the
ost cost-effective management programs.
Ferrante et al. (1) point to the possibilities for improving
utcomes for the growing population with HF. They offer
eeper understanding of the program components that drive
enefits and help us to conceptualize the most clinically
ffective strategies. Finally, they challenge us to reconstruct
ur health care system into one that aligns providers to offer
ntegrated, multidisciplinary, cost-effective programs—
ncluding empowerment of patients themselves—to gener-
te a sustained improvement in health care outcomes.
eprint requests and correspondence: Dr. Marvin A. Konstam,
ufts Medical Center, Box 108, 800 Washington Street, Boston,
assachusetts 02111. E-mail: mkonstam@tuftsmedicalcenter.org.
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